Genmab

View All

epkinly-approval-for-dlbcl-treatment
Abbvie-Genmab’s EPKINLY Approval for DLBCL Treatment: The First CD20XCD3 Bispecific Antibody

Abbvie-Genmab’s EPKINLY, the first CD20XCD3 Bispecific Antibody gets US approval for Relapsed/Refractory DLBCL treatment. Roche’s Glofitamab is expected to garner benefits in Europe first. Let's have a glimpse of evolving DLBCL treatment landscape in Relapsed/Refractory setting and if bi-specific as a class can be...

Find More

pharma-news
AbbVie & Genmab’s Collaboration; Lilly’s antisense neuro deal; COVID-19 treatment updates; Roche’s partnership with Innovent;

AbbVie Seals a USD 750 M Bispecific Antibody Cancer Drug Deal with Genmab   AbbVie is set to reimburse Genmab USD 750 million upfront for a stake in a pipeline of anti-cancer bispecifics that is led by epcoritamab. The agreement features up to USD 3.2 billion in milestones, positions AbbVie to race Reg...

Find More

TRAIL-Receptor-Agonists
TRAIL Receptor Agonists: Emerging target therapies against Cancer

Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL), also known as Apo-2 ligand (Apo2L) is a type II trans membrane protein belonging to the Tumor Necrosis Factor (TNF) superfamily that are widely expressed on the surface of Natural Killer (NK) and T cells, macrophages and dendrite cells. These pr...

Find More